YourCOMPLETEcontinuum of care!
You may find the following websites useful when trying to choose a Skilled Nursing Facility or for additional financial information:
Influenza and Pneumonia Vaccination Recommendations:
The Influenza vaccine is usually administered between October and March each year; however, some years the CDC may recommend
that the vaccine be administered earlier. It is recommended that you take the vaccine as early in the Fall as possible so your body has
time to develop immunity towards the seasonal Flu before the Flu is prevalent in your area. The Influenza (Flu vaccine) is very safe,
effective, and generally has few side effects. You cannot get the Flu from the Influenza vaccine. There may be mild side effects such as
soreness, redness, or swelling at the injection site. Other possible side effects include headache and low-grade fever. As with any medication,
there are very small risks that serious problems could occur. However, the potential risks associated with the Flu are much greater than the
potential risks associated with the Influenza vaccine.
Note: The Flu vaccine is NOT recommended for people who have a serious allergy to eggs or have had a reaction to a previous Flu vaccine. People who
have a moderate or severe illness with a fever should wait to get vaccinated once their illness has resolved.
The Pneumonia vaccine is recommended for adults age 65 years or older who have not previously received a pneumococcal vaccine.
If the previous vaccination history is unknown, adults should receive a dose of PCV13 (Prevnar13) first, followed by a dose of PPSV23(Pneumovax23).
The dose of PPSV23 (Pneumovax23) following the PCV13 (Prevnar13) should be given 6-12 months after the dose of PCV13 (Prevnar13)
or anytime later than 12 months. Both vaccines should not be given at the same time, and the minimum acceptable interval between PCV13 (Prevnar13)
and PPSV23 (Pneumovax23) is 8 weeks. Adults age 65 years or older who have previously received one or more doses of PPSV23 (Pneumovax23)
also should receive a dose of PCV13 (Prevnar13) if they have not yet received it. A dose of PCV13 (Prevnar13) should be given 1 year after receipt
of the most recent PPSV23 (Pneumovax23) dose. For those for whom an additional dose of PPSV23 (Pneumovax23) is indicated, this subsequent
PPSV23 (Pneumovax23) dose should be given 6-12 months after PCV13 (Prevnar13) and 5 years after the most recent dose of PPSV23 (Pneumovax23).
There may be mild side effects such as redness or pain where the injection is given. Less than 1% of people who take the vaccine develop a fever,
muscle aches, or more severe local reactions. Like any medication, a serious reaction could occur including serious harm or death, but this risk is extremely small.